At CEDSA, we are committed to supporting such important research development through provision of information and fundraising initiatives.
Edimer Pharmaceuticals is a U.S.-based company in Cambridge, Massachusetts that is doing innovative research into X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Researchers at Edimer are dedicated to making an impact for future generations affected by XLHED through the development of EDI200, a protein engineered to replace the naturally occurring ectodysplasin A that is deficient in patients with XLHED. Edimer is led by a team of seasoned biotechnology industry veterans with experience in drug development complemented by a strong network of world-class clinical and scientific advisors.
Edimer Pharmceuticals has also sent CEDSA the following information for our members. “As part of an ongoing commitment to the X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) community, Edimer Pharmaceuticals has launched the XLHED Network – a web site dedicated to patients and families affected by XLHED and their healthcare providers.” Information about Edimer Pharmceuticals, the XLHED Network and a link to the Network website are all listed below.
Edimer Pharmaceuticals Website
The XLHED Network Fact Sheet
Click here to open the PDF
The XLHED Network Website